Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1720-8386
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience ; day:20 ; month:5 ; year:2021 ; pages:1-7
Journal of endocrinological investigation ; (20.5.2021), 1-7
- Creator
-
Sala, E.
Carosi, G.
Sindaco, G. Del
Mungari, R.
Cremaschi, A.
Serban, A. L.
Ronchi, C. L.
Ferrante, E.
Arosio, M.
Mantovani, G.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40618-021-01562-z
- URN
-
urn:nbn:de:101:1-2021091821560839489662
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sala, E.
- Carosi, G.
- Sindaco, G. Del
- Mungari, R.
- Cremaschi, A.
- Serban, A. L.
- Ronchi, C. L.
- Ferrante, E.
- Arosio, M.
- Mantovani, G.
- SpringerLink (Online service)
Other Objects (12)
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome
Somatostatin analogues labeled with copper radioisotopes: current status
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Differences in somatostatin receptor subtype expression in patients with acromegaly : new directions for targeted therapy?
Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome
Somatostatin analogues labeled with copper radioisotopes: current status
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Differences in somatostatin receptor subtype expression in patients with acromegaly : new directions for targeted therapy?
Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome
Somatostatin analogues labeled with copper radioisotopes: current status
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Differences in somatostatin receptor subtype expression in patients with acromegaly : new directions for targeted therapy?